Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience
We present real-world data on patients switching from anti-CD20s to fumarates for various motivations in this retrospective observational study of 43 patients from three multiple sclerosis centers. Recurrent infections on anti-CD20s were the most common reason for switching to fumarates. Patients experienced limited disease activity on fumarates (83.7% were free from relapse and new MRI lesions), suggesting effectiveness was maintained. Of the 16.3% with disease activity on fumarates, 57.1% also had disease activity on anti-CD20s. Tolerability was the main reason for discontinuing fumarates. Future studies will provide additional insight into how to effectively and safely transition from anti-CD20s to fumarates.
Authors
- T. Eoin West (ORCID: https://orcid.org/0000-0001-5503-7204)
- Josef Gutman (ORCID: https://orcid.org/0000-0002-7931-3098)
- Jason P. Mendoza (ORCID: https://orcid.org/0000-0003-2526-5542)
- Tammy Hoyt
- Enrique Álvarez (ORCID: https://orcid.org/0000-0001-5854-9643)
- James B. Lewin (ORCID: https://orcid.org/0000-0002-2352-9113)
- Brandi Vollmer (ORCID: https://orcid.org/0000-0002-0593-9012)
- Evan L. Riddle
- Monica Benitez
Institutions
- Intermountain Healthcare (US)
- Biogen (United States) (US)
- NYU Langone Health (US)
- Rocky Mountain Multiple Sclerosis Clinic (US)
- Multiple Sclerosis Center Of Northeastern New York (US)
- Rocky Mountain MS Center (US)
- University of Colorado Anschutz Medical Campus (US)
- Columbia University (US)
Publication Details
- Journal
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/20552173251371808
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00